biotech · Lupus Nephritis - WHO Class III · Non Hodgkin Lymphoma · ARTV
Artiva Biotherapeutics drug portfolio — 9 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Portfolio lens on 9 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Artiva Biotherapeutics drug portfolio — 9 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Antineoplastic and immunomodulating agents (L01) compound in Artiva Biotherapeutics's portfolio. Mechanism: Somatic cell supplemental therapy.
US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M1.
US regulatory status: approved. Mechanism: Unknown.
Development asset linked to Artiva Biotherapeutics in public FDA and regional records.
US regulatory status: approved. Molecular target: DNA.
Development asset linked to Artiva Biotherapeutics in public FDA and regional records.
US regulatory status: approved. Molecular target: DNA polymerase (alpha/delta/epsilon).
US regulatory status: approved. Molecular target: B-lymphocyte antigen CD20.
Development asset linked to Artiva Biotherapeutics in public FDA and regional records.